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C M E Table, page 713) .
In what follows, we will defi ne the language medical researchers commonly use to describe the association between T and D in the population, and consider and compare common measures of two-by-two association, and how they are estimated and interpreted for positive association. The purpose of doing so is to review such methods, but more so, to point out many common errors made in this context that may cost the health, well-being, and perhaps even lives of patients.
THE BASIC TERMS
In the two-by-two table, there are four outcomes: TP represents the probability of a "true-positive result," FN that of a "false-negative result," FP that of a "false-positive result," and TN that of a "true-negative result."
The probability that D = 1 is the "baserate" P, which, depending on how the outcome is defi ned, may be a prevalence or an incidence in the population of interest. The probability that T = 1, is called the "level" Q. The level of a test is determined by how loosely or stringently the criteria for a positive test are set, and often can be varied by the decision of the researchers.
When the results in the two-by-two table are consistent with random decision making, TP = P•Q, FN = P•Q', FP = P'•Q, FN = P'•Q'. Rational and highquality decision making requires that one do a lot better. Ideally, of course, one would want to make no wrong decisions, ie, that TP = P = Q and TN = P' = Q', and FN = FP = 0, but this can seldom happen in medical applications because the criterion D is seldom measured with perfect reliability.
Perhaps the sole issue concerning two-by-two tables on which everyone tends to agree is how to test the null hypothesis of random association between T and D: some variation of the two-bytwo chi-square test. However, our focus is not on "proving" non-randomness. By the time there is scientifi c rationale and justifi cation for proposing such a test, the null hypothesis of randomness will seldom be absolutely true.
1,2 Any non-random association (no matter how weak) is likely to be "statistically significant" at whatever level specifi ed, provided only that the sample size is large enough. The question at issue here is one of assessing clinical signifi cance. That's where the disagreements begin, largely for reasons having to do with the now well-recognized problems with the use of statistical signifi cance tests.
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SENSITIVITY, SPECIFICITY, AND PREDICTIVE VALUES
Sensitivity (Se), specifi city (Sp), and the predictive values of a positive and negative test (PVP and PVN) are commonly used measures to describe the association between T and D and are defi ned in the Table (see page 713 ). It still occasionally happens in the medical literature that these terms are interchanged, or that different names are used. For example, the "true positive rate" might refer to TP, or to sensitivity, or to PVP. The defi nitions presented here are standard defi nitions, but readers of the medical literature must still check the defi nitions given in each text.
Only if P = Q is Se = PVP and Sp = PVN, and only if P = Q = 1/2 are all four of these probabilities the same. Generally, Se, Sp, PVP, and PNV are different numbers and can vary widely from each other.
All the probabilities (TP, FN, FP, TN) within the two-by-two table can be expressed in terms of (P, Se, Sp) or in terms of (Q, PVP, PVN) (see Table, page 713). Thus, Se and Sp can be expressed in terms of Q, PVP and PVN, and PVP and PVN can be expressed in terms of P, Se, Sp (Bayes' theorem). For example, applying the defi nition of PVP but using the cell probabilities expressed in terms of P, Se and Sp: PSe PSe + P'Sp' PVP = It is an easy matter to get either sensitivity or specifi city near 1. Give everyone a positive test (T = 1) to get a sensitivRational and high-quality decision making requires that one do a lot better.
ity of 1.0; give everyone a negative test result (T = 0) for a specifi city of 1.0. A high sensitivity or specifi city or PVP or PVN alone does not guarantee the accuracy of the test. The trick is to get a test with both high enough sensitivity and high enough specifi city, or both predictive values high enough, and that is not easy, particularly since "high enough" is so vaguely defi ned. With random decision making, Se = Q, Sp = Q', PVP=P, PVN=P'. Thus all four of these indices (Se, Sp, PVP, PVN) are uncalibrated measures [ie, their random value depends on either the baserate (P) or the level (Q)]. Yet it still happens in the literature that only specifi city, or only sensitivity is reported, which is somewhat like reporting a temperature, but forgetting to report whether the scale was Fahrenheit, Celsius, Kelvin, or on some other temperature scale.
We can standardize these four measures, exactly as we would recalibrate Fahrenheit or Kelvin readings to the standard Celsius scale, treating random as the "freezing point," perfect decision making as the "boiling point." Recalibrated sensitivity is: (Se-Q)/Q'; recalibrated specifi city is (Sp-Q')/Q; recalibrated PVP is (PVP-P)/P'; recalibrated PVN is (PVN-P')/P. Then, it turns out that rescaled sensitivity and PVN are exactly the same number, as are rescaled specifi city and PVP. Those who choose to report sensitivity/specifi city and those Risk Ratios
Population Defi nitions of the Basic Probabilities Used in the Evaluation of a Test (T) against a Criterion (D) and Defi nitions of Common Effect Sizes with their
RR1 = Se/(1-Sp) k(0) = (RR1-1)/(RR1 + P'/P) RR2 = Sp/(1-Se) k(1) = (RR2-1)/(RR2 + P/P') RR3 = PVP/(1-PVN) k(1) = (RR3-1)/(RR3 + Q'/Q) RR4 = PVN/(1-PVP) k(0) = (RR4-1)/(RR4 + Q/Q') Phi = (TP TN-FN FP)/(PP'QQ') 1/2 k(w*) = Phi = (k(0)k(1)) 1/2 ; w*= [(PP'QQ') 1/2 -P'Q]/(PQ'-P'Q)
Odds Ratio = (TP TN)/(FN FP)
3907Kraemer1CS. 12 Cohen noted that in the two-by-two situation, the costs or risks associated with two types of errors in any population are often very different. He introduced an index that incorporates consideration of such relative costs into the assessment of the association: the weighted kappa k(w).
The weight in this kappa, w, is some number between 0 and 1 that refl ects the relative importance of avoiding false negatives to avoiding false positives.
13,14 How much difference does it make to those who will have the outcome whether or not they have a positive test (avoiding a false negative)? How much difference does it make to those who will not have the outcome whether or not they have a negative test (avoiding a false positive)? Of these two, how much more important is one than the other? This is a clinical judgment based on assessment of what the sequelae will be for a positive and for a negative test in the population of interest.
The default value for w is 1/2. In a situation in which one is primarily concerned with avoiding false negatives, w approaches 1; in a situation in which one is primarily concerned with avoiding false positives, w approaches 0. When both types of errors are of about equal concern, w = 1/2, the most common situation.
The defi nition of k(w) 15 appears in the Table (see page 713 ). Note that the numerator of k(w) does not actually depend on the weight w; only the reference value in the denominator does. Moreover, k(w) is a weighted average of k(1) (rescaled sensitivity or PVN) and k(0) (rescaled specifi city or PVP), with weights determined by P, Q, and w. When P = Q, all values of k(w) are equal, regardless of what w is. Finally when k(w) = 0 for one value of w, k(w) equals 0 for all values of w. In any case, the magnitude of k(w) indicates how far between random and perfect a particular test is, when the errors are weighted as specifi ed by w. There are no fi xed standards for judging the magnitude of k(w), and generally one test is either compared with another test or against the quality of D regarded as a "gold standard."
INVARIANCE ISSUES
The values of all these probabilities and k(w) vary from one clinical population to another. That P varies is, of course, no surprise. Men are more likely to develop schizophrenia; women to develop depression, etc. That Q varies roughly paralleling P, is welcome: one would hope to have more positive tests in populations where there are more positive diagnoses. It is well understood that PVP and PVN vary from one population to another, typically with PVP increasing roughly as P increases, and with PVN decreasing.
What is more likely to be surprising, although it shouldn't be, is that the sensitivity and specifi city of a test evaluated against the same diagnosis vary from one clinical population to another. [15] [16] [17] [18] If the test is reasonably accurate for D, sensitivity tends to increase as P (and Q) increase, and specifi city to decrease, although there is no exact functional relationship between P and either sensitivity or specifi city across different clinical populations. It is quite possible that two populations with very similar base-rates (P) will have very different sensitivities or specifi cities, while two populations with very different base-rates may have quite similar values. It is one of the longest lasting and most tenacious myths in medical science that the sensitivities and specifi cities for a particular test evaluated against a particular diagnosis are test constants, the same in any clinical population.
So pervasive is this myth that medical students are sometimes required to demonstrate that they believe this myth on the medical board exam. Their question goes something like this: Suppose that it has been shown in one population that the sensitivity of a test is 90% and its specifi city is 80%. Now it is proposed to use that test in a different population in which the prevalence of the disorder the test is meant to detect is 2%. In this latter population, what percentage of those with positive tests is likely to have the disorder?
What the question is meant to elicit is demonstration of the understanding of the defi nitions of prevalence, sensitivity, specifi city, predictive values, and Bayes' theorem. Thus, the answer that will be counted as correct is that since the sensitivity was 90% and the specifi city was 80% in the population with 2% prevalence, PVP = 8.4%. However, the correct answer is that there is insuffi cient information to answer their question. The fact that the sensitivity of that test is 90% and the specifi city is 80% in another population does not tell anything about the sensitivity and specifi city of the test in this population with prevalence 2%.
RISK RATIOS, RISK DIFFERENCES, NNT
To make matters worse, there is also a proliferation of other measures (and more being suggested each year) to describe the association between test and diagnosis, measures that do not necessarily agree with each other.
There are, for example, two risk differences (see the Table, page 713), which are usually different from each other, and from k(0), k(1/2) or k(1). However, it is easy to show that mathematically RD1 = k(P'), and RD2 = k(Q).
When comparing two or more tests against the same diagnosis in the same population (P fi xed), RD1 often seems a reasonable choice. It is less reasonable to use RD2, because the weight RD2 places on false negatives versus false positives refl ects the researchers' often arbitrary choice of test criterion (the level Q). This changes from one test to another when evaluated against the same diagnosis in the same population, making it impossible to compare tests.
Number Needed to Take (NNT) equals 1/RD1, and is the number needed to take with D = 1 to fi nd one more T = 1 than if the same number were taken with D = 0. 19 Thus, random association approaches infi nity; perfect association has NNT = 1. This measure is useful to convey clinical meaning to clinicians and medical consumers, because the units are patients rather than probability points, but in computations, is difficult to use. Its mathematical equivalent, RD1, is preferable.
In addition, there are also four risk ratios (see the Table, page 713). Risk ratios are on a completely different scale from the k(w) or the risk differences, where a value of 0 indicates random association, +1 perfect positive association and -1 perfect negative association. For the risk ratios, the value indicating random association is 1, and perfect-positive association would be indicated by a risk ratio approaching infi nity, perfect negative association by a risk ratio approaching zero. The infi nite scale in one direction, and the asymmetry of positive (1 to infi nity) and negative (0 to 1) association, makes judging the magnitude of any risk ratio very diffi cult.
However, that problem is easily resolved, for a non-linear recalibration of the risk ratios that controls for how rapidly the various risk ratios increase from 1 to infi nity (or decrease from 1 to 0) aligns them exactly with the k(w) (see Table, page 713). In brief, once each risk ratio is recalibrated, it is equivalent to either k(0) or k(1). Thus all four risk ratios from any two-by-two table, disparate though they may be from each other, are meaningful, but fi rst require recalibration using the appropriate row or column probability, which reduces the four to two, and, after that, which of the two is relevant (if either) depends on the choice of the weight w.
WHAT OF THE PHI COEFFICIENT?
In behavioral research, less so in medical research, a common index used to describe the strength of association in this situation is the phi coeffi cient, the product moment correlation coeffi cient between T and D. The phi coeffi cient is the geometric mean of the two extreme kappa coeffi cients: phi = (k(1)k(0)) 1/2 . If P = Q, then k(w) are all equal to each other, and all equal the phi coeffi cient. Otherwise, phi = k(w*) where w* (see Table, page 713) depends on how close P and Q are to each other. Thus, as was the case with RD2, the weight w will vary with the choice of Q, and like RD2, phi is not recommended.
One fi nal comment on phi: If a representative sample from the population is used for estimation, then the chi-square statistic X = N • phi 2 , where phi is the sample phi estimate, can be used to test the null hypothesis that the population phi is zero. Because the power to detect deviations from randomness depends in part on the relative sizes of P and Q, phi, rather than any of the other measures of two-by-two association, is most closely related to testing the null hypothesis of randomness. However, if the sample is stratifi ed, the relationship between the chi-square statistic and population phi no longer holds, for the chi-square statistic will then refl ect the researchers' choices of sample sizes in each stratum, but the population phi coeffi cient, of course, does not.
WHAT OF THE ODDS RATIO?
Finally there is the Odds Ratio (OR), 20 perhaps the most commonly used indication of strength of association in medical research. Below are 5 equivalent formulas for the Odds Ratio, all equivalent to that in the Table (see page 713 The Odds Ratio has the same scale as do the Risk Ratios. However, because OR is the product of two Risk Ratios, for positive association OR is always bigger than the biggest risk ratio. Thus, Odds Ratio often conveys the impression of much stronger association than any of the other known measures of two-by-two association. This may be one of the reasons for its continued popularity in the face of considerable evidence suggesting how problematic its behavior is for assessing association in two-by-two tables.
When comparing two or more tests against the same diagnosis in the same population, RD1 often seems a reasonable choice.
Moreover, the relationship between Odds Ratio and the Risk Ratios has led to a widely held misperception, that the Odds Ratio is approximately the same as the largest Risk Ratio. Researchers often even interchange the labels Odds Ratio and Risk Ratio. It is true that when P is near zero or near 1, the Odds Ratio approximates the largest Risk Ratio, but this happens only because another Risk Ratio is near its null value of 1. If RR3 = 10 and RR4 = 1.01, for example, then clearly Odds Ratio = 10.1 is approximately equal to RR3. However, which of the two risk ratios here is the one to believe? Since rescaled RR3 equals k(0) and rescaled RR1 equals k(1), the answer to that question depends crucially on which of the two errors is considered clinically more important, an issue completely ignored by the Odds Ratio.
In the very special case when P = Q = 1/2, not only are all the k(w)'s the same for all values of w, but they all equal Yule's Index:
To correct the asymmetry in the OR scale, and the problems associated with a measure with infi nite range, as well as to facilitate comparison with other measures of association, Y seems the best choice of rescaling the Odds Ratio to the standard (0,1) scale.
What then can be said about Y? 1) When P = Q = 1/2, Y equals k(w) for all values of w; 2) With random association Y is zero, as are all the k(w). 3) Y and all the k(w) always have the same sign. 4) Y is always greater than k(P'). 21 However, Y may approach 1 when association is far from perfect, indeed often when most other measures of association indicate near random association.
One way of re-expressing k(w) is: (ie, same numerator, different denominators). Thus, the basic difference between k(w) and Y is that the reference value in the denominator for k(w) depends on the baserate (P), how loosely or stringently the criteria for T are set (Q) and the relative clinical importance of false negatives to false positives (w), while the reference value for Y depends heavily on how closely one or the other of the error rates (FP and FN) comes to zero. Any situation in which Q<<P, or Q>>P will force one of the error rates toward zero, Y may approach 1 (Odds Ratio approaching infi nity), even if that error rate corresponds to the error of least clinical importance.
The Odds Ratio appears to have been introduced originally as the likelihood ratio test statistic to test the null hypothesis of randomness comparing two Binomial distributions. The magnitude of an Odds Ratio unequal to 1, however, is uninterpretable as an effect size. Nevertheless, there are still many useful applications of the Odds Ratio, for example, it is an excellent indicator of non-randomness (eg, in Logistic Regression Analyses).
Moreover, unlike every other measure of two-by-two association, population Odds Ratio can be estimated (even with the same computation) from a representative sample, a prospective stratifi ed sample or a case-control sample, provided all three are unbiased samples with unbiased measurements from the same population. 22 This is a computational convenience, that has led to a serious misunderstanding.
Because the estimation of Odds Ratio in a sample is not affected by the percentage of the sample selected with and without the diagnosis in an unbiased casecontrol study, it is often suggested that the Odds Ratio in the population does not depend on the baserate P, and thus that Odds Ratio is invariant over populations with different P. This claim is clearly not true for k(w), and k(w) has often been criticized because of its "dependence on baserate." However, Odds Ratio, like k(w), relating a test and diagnosis in different clinical populations, is not a constant. [16] [17] [18] This particular misunderstanding may also have arisen in part from the myth that sensitivity and specifi city for a particular test evaluated against the diagnosis are constants across different clinical populations, since OR can be computed using only Se and Sp.
All things considered, we strongly recommend against use of the Odds Ratio (or Y) for the evaluation of medical tests, 20, [23] [24] [25] [26] but this should not limit its use for other previously noted more appropriate applications in medical research.
DESIGN, SAMPLING, AND ESTIMATION ISSUES Design Issues
When a test is meant to detect a condition that exists at the time of testing (a diagnostic test), T and D are both assessed within a time span short enough that the situation does not change during that time. When a test is meant to predict a condition that may or may not occur in the future (a prognostic test), the test (T) is done at one time point and the subject followed prospectively to a later time point at which D is determined. In either case, to avoid measurement bias, the determinations of T and D should be done "blinded" to each other to avoid pseudocorrelation due to bias in the raters.
Naturalistic Sampling
If a representative sample is drawn from the population of interest and T and D observed for each subject in the sample, each of the probabilities in the Table (see page 713 ) can be estimated by substituting the proportions of the sample seen in each cell of the two-by-two table for the corresponding probability in the population defi nition. For accuracy of estimates, sample sizes must be particularly large when the baserate, P, or the level, Q, is either very small or very large.
Prospective Stratifi ed Sampling (Two-stage Sampling)
When P is very small, and/or D can be determined only with great diffi culty or cost, prospective stratifi cation is an effi cient option. Suppose we proposed to sample a large sample of subjects from the population of interest and assess T (Stage 1). From this sample we can estimate Q, the level of the test. Then (Stage 2), we can randomly sample N1 from among those with T = 1, and randomly sample N0 from among those with T = 0, over-sampling the rarer result for assessment of D. From the second stage sample we can estimate PVP and PVN and thus RD2, RR3, RR4 and Odds Ratio, but not P,Q, sensitivity, specifi city, or any of the k(w).
Without P we cannot recalibrate PVP and PVN. Without Q, we do not know what the value of the weight is for RD2=k(Q). However, combining the estimate of Q from Stage 1, and the estimates of PVP and PVN from Stage 2, we can estimate all the cell probabilities, and thus all the probabilities and consequently all the k(w).
Having Stage 1 satisfi es two crucial needs: 1) to generate representative samples of those within the population with T = 1 and with T = 0 for Stage 2, and 2) to obtain an unbiased estimate of Q in this population. Without satisfying both of these needs, the assessment of the quality of the decision process can be badly fl awed. In short, approaching the evaluation of a test using prospective stratifi ed sampling is quite viable and in many cases advisable, but the sampling must be done with the full two-stage sampling approach and an estimation procedure appropriate to that sampling approach used.
Retrospective Stratifi ed Sampling (case-control)
The situation with respect to retrospective stratifi ed sampling is quite dif- If there were neither a sampling bias nor a measurement bias, from a casecontrol study, one could estimate Se, Sp, RD1, RR1, RR2 and Odds Ratio, but not P,Q, the predictive values, or any of the k(w) other than RD1 = k(P'). This is the context in which Odds Ratio was recommended. But why not recommend RD1 = k(P') rather than Odds Ratio? Generally, advocates of the Odds Ratio point out that RD1 in such situations tends to be very small, while Odds Ratio tends to be very large, a questionable logic. However, proposing the use of RD1 in place of Odds Ratio would not solve the problem in any case, for it is diffi cult to avoid the sampling biases and measurement biases of case-control studies.
A case-control study meant as an exploratory study to investigate the possibility of non-random association between T and D in a population may be very useful as a preliminary to proposing generating a naturalistic sample or designing a two-stage prospective sample in the population in a future study. However, to assess the quality of decision-making, we recommend against a case-control design.
Estimation
For either prospective design, it is important not only to derive a point estimate of the appropriate k(w), but to recognize its estimation error, by presenting a confi dence interval estimate. The best current approach is to use a bootstrap method [27] [28] [29] appropriate to the sampling method.
CONCLUSION
Clearly, the discussion leads to recommendations about appropriate sampling, measurement, design, analysis, and presentation and evaluation of results. Rather than repeating these, let us instead indulge in a fl ight of fancy on "How to Lie with Statistics." 30 Suppose someone really wanted to demonstrate a strong association between some test (T) and an outcome (D) and didn't much care how. What would they do? First of all, they would set the criterion for T = 1 stringently (Q<<P or Q>>P) to force one of the error rates toward zero. Then, they would do a case-control study with a very large sample size, using inclusion/exclusion criteria that assure that the "cases" are sure to have D = 1 and the "controls" sure to have D = 0. Such two samples are more likely to represent the extremes of the population, which will exaggerate any appearance of association, although unlikely to produce an association where there is none. Then, in the informed consent process, researchers would emphasize the scientifi c and empirical evidence to date that T is associated with D, and then use retrospective recall for T. What this does is to induce "cases" to be much more sensitive to the possibility that T = 1 in their past, which will tend to result in over-reporting in that group. This too serves to exaggerate association, now perhaps even inducing the appearance of association when there is none. Then, they would use the Odds Ratio as the measure of association, because Odds Ratio will indicate association much stronger than any other measure of association, particularly under the above circumstances.
Finally, there is precedent to overstating the interpretation of the magnitude of whatever Odds Ratio is obtained. An Odds Ratio of 1.5 is often regarded as "large," even though it corresponds only to Y = .1 (It is sometimes even described as a 50% increase in risk.) If the Odds Ratio has (by such infl ated standards) a "large" magnitude, but is not statistically signifi cant despite the large sample size, one would emphasize the Odds Ratio and ignore the P value (perhaps reporting a "trend"). If the Odds Ratio has an admittedly small magnitude (ie, 1.1, Y = .02) but is statistically signifi cant (which is likely with a large sample size), one would emphasize the P value and ignore the magnitude of the Odds Ratio.
In neither case, would one present any other descriptive statistics (eg, the sensitivity/specifi city or predictive values), or discuss the potential impact on clinical decision making (w), because that might raise doubts about the clinical value of the test, whatever its Odds Ratio.
Unfortunately, this may be remarkably close in some respects to the way many epidemiological studies, genetic studies, and medical test evaluations have been conducted in the past, and may help explain why such studies are so diffi cult to replicate or confi rm.
In contrast, how would we conduct a rigorous evaluation of T against D? One would begin by proposing to obtain a representative sample from the population of interest, with (T,D) evaluated by two different evaluators, done in such a way that neither affects the other's decision. In dealing with a rare event, we might propose two-stage sampling as done above, estimating P from the fi rst stage, and then PVP and PVN from the second stage, combining these to estimate the four probabilities of the twoby-two table. We would then consider the relative importance of false positives versus false negatives, and set w. Then, we would proceed to execute the study, to estimate probabilities in the two-bytwo table and to compute the appropriate k(w) from the data. To get 95% twotailed confi dence intervals, we would use a bootstrap procedure. If zero is not contained within that confi dence interval we would be assured that association was "statistically signifi cant" at the two-tailed 5% level. To assess the clinical signifi cance of the fi nding, we might compare the estimated k(w) against the intraclass reliability kappa for D, or against other possible tests for D.
The results would undoubtedly be far less exciting than those from the fi rst study, but would likely be closer to the truth, and more likely to be replicable across future studies.
